[02/15] Agios Pharma (AGIO) Results Will SkyRocket Stock (Strong Buy) 💪👌🚀
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 15, 2024, at 8:00 a.m. ET to report its fourth quarter and year end 2023 financial results and other business highlights.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has TMPRSS6 siRNA as a potential treatment for polycythemia vera, a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU), and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.
Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to announce Q4 earnings results on Thursday, February 15th, before market open.
The consensus EPS Estimate is -$1.64 and the consensus Revenue Estimate is $7.92M
Over the last 1 year, AGIO has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time.Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.
More on Agios Pharmaceuticals
Agios Is A Gem, But It Will Need Patience (Rating Upgrade)
Agios Pharmaceuticals: Strong Thalassemia Data Makes A Tempting Bull Case
AIM stock dips amid mixed results for post-COVID fatigue therapy
CRISPR, bluebird stocks slide as Agios rallies on thalassemia study.
Modify on 2024-02-15 12:15
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
